Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABEO Abeona Therapeutics
2.760-0.060-2.13%
Close
02/03 16:00 ET
2.7600.0000.00%
Post Mkt Price 02/03 16:00 ET
High
2.900
Open
2.770
Turnover
448.60K
Low
2.720
Pre Close
2.820
Volume
158.45K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Abeona Therapeutics Files for Offering of 15.2M Shares by Sellers
PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common t
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Abeona Therapeutics (ABEO)
Abeona Therapeutics Is Maintained at Market Perform by SVB Leerink
Abeona Therapeutics Is Maintained at Market Perform by SVB Leerink
SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6
SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $5 to $6.
Abeona Therapeutics Q3 EPS $(1.48) Up From $(3.50) YoY
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(1.48) per share. This is a 57.71 percent increase over losses of $(3.50) per share from the same period last year.
Abeona Therapeutics: Cash Runway Into 3Q 2024 >ABEO
Abeona Therapeutics: Cash Runway Into 3Q 2024 >ABEO
Abeona Therapeutics 3Q Loss/Shr $1.48 >ABEO
Abeona Therapeutics 3Q Loss/Shr $1.48 >ABEO
Press Release: Abeona Therapeutics Reports Third Quarter 2022 Financial Results
Abeona Therapeutics Reports Third Quarter 2022 Financial Results Following positive topline data from Phase 3 VIITAL(TM) study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA
Abeona Therapeutics (NASDAQ:ABEO) PT Raised to $40.00 at Cantor Fitzgerald
Abeona Therapeutics (NASDAQ:ABEO – Get Rating) had its price objective upped by investment analysts at Cantor Fitzgerald from $22.00 to $40.00 in a note issued to investors on Tuesday, The Fly repor
Company Overview
More
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
CEO： Mr. Vishwas Seshadri
Market： NASDAQ
Listing Date： 12/19/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet